Subcutaneous Fat Clinical Trial
Official title:
Effects of Ultrasound Cavitation Focused on Located Adiposity: Pilot Study
The aim of this study is to evaluate the effect of cavitation ultrasound focused on localized adiposity and its effects associated with stereodynamic lymphatic drainage. The investigators aim also to know if this procedure will influence the biochemical profile of the individuals concerned, as well as whether it will be found difference between the group that will receive focused ultrasound cavitation associated with stereodynamic drainage and the group will receive only focused cavitation ultrasound.
This study will be a double-blind randomized clinical trial, preceded by a pilot study due
to lack of data in the literature impossible to calculate the size of adequate sample.
The overall objective of the study is to evaluate the effect of cavitation ultrasound
focadalizado in localized adiposity and its associated lymphatic drainage effects
stereodynamic.
The specific objectives are:
Evaluate and compare the effects of focused ultrasound cavitation in reducing hypodermic
layer and anthropometric measurements of women; To evaluate the acute and chronic effects of
the technique; To evaluate the reduction in adipose tissue layer from the ultrasound image;
Evaluate and compare the reduction of the fat layer through intergroup and intragroup
photographic image; Evaluating and comparing serum biochemical parameters (total
cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, glucose, urea and creatinine)
of women undergoing focused ultrasound cavitation; Evaluate and compare the technical
efficiency in group A (without stereodynamic drainage) and B (with stereodynamic drainage).
This study will be conducted with 28 volunteers, respecting the criteria for inclusion and
exclusion previously cited by reading and signing of the free and clear consent.
Participants will be divided into 02 groups randomly. Randomization will be performed by
using the local random distribution www.random.org tool, in order to prevent the researcher
to identify which intervention will be performed on each patient. The generation of sequence
numbers shall be made by the researcher "blind" to the study, after the selection of
patients for inclusion and exclusion criteria. The sequence numbers to be used for
randomization will be kept confidential until such time as the intervention Participants
will undergo a 4-week control period between the first (base) and the second evaluation
(pre-treatment), so each participant It will be their own control, ensuring that the
possible changes that may be found at the end of the project will be related to the
procedure and not influenced by lifestyle habits. During the period the research subjects
will be instructed not alterararem their respective routine activities.
08 sessions will be conducted Cavitational Focused Ultrasound in individual applications,
once per week, total of 08 weeks of treatment. The first collection (pre-treatment) will be
only to carry out the data collection.
Data collection will consist of:
- Questionnaire of habitual physical activity Baecke - in the base period will be asked
participants to answer this quiz to knowledge of their routine physical activity;
- Perimetry - anthropometric measurements will be measured by a previously trained
evaluator. During the measurement of the circumference of the tape will be adjusted to
the body, directly on the skin in order to provide more reliable measurements possible,
without the occurrence of tape pressure on subcutaneous tissue causing deformity. These
data will be verified in four stages: pre-treatment, before the first session after the
first session and after the eighth treatment session. They will be measured:
Height: will be determined by the balance rule coupled with a degree in 1 mm, with the
individual back to this, in an upright standing position, feet together, and trying to put
the posterior surface of heels, pelvic and shoulder girdle contact instrument; Body weight
will be measured through traditional mechanical scale with 100g graduation, with front man
for the same, in the upright position, feet together, wearing light clothes and without
shoes; Body Mass Index (BMI) - Based on height and weight will be held calculate BMI, kg ÷
height x height; Abdominal skin fold, used to estimate the percentage of body fat will be
taken using caliper. It will be measured abdominal crease, having as anatomical reference
umbilicus, plying up the region located 1 to 3 cm to the right of scar parallel to the
longitudinal axis of the body; Waist circumference will be measured using the measuring tape
positioned parallel to the ground, where the measurement is taken over previous iliac crests
5 cm above the previous iliac crests 10 cm above the iliac crest and waist earlier; Hip
circumference, the tape measure is parallel to the ground and positioned in terms of points
of trocantéricos right and left, while the individual will be assessed with feet together;
Thigh circumference will also feature the same principles described above, but will be used
as an indication of circumference changes that are unrelated to treatment, such as changes
induced by weight loss.
- Bioimpedance - Evaluations shall be performed by a professional with training and
experience in this type of analysis. Obtaining the bioimpedance will take place in two
stages: in the base period (pre-treatment) and after the end of treatment (after the
eighth session). For the examination, it will be used Maltron BF-900 model system and
will be adopted the protocol recommendations proposed by the European Society for
Clinical Nutrition and Metabolism: To assess body mass and height of the individual at
the time of examination; Fasting individual and not drink alcohol for at least 8 hours;
Urinate before the exam; Not perform physical exercise in the eight hours before the
test; No injury to the skin where the electrode will be; Clean the skin with alcohol;
Position the electrodes always on the same side of the body; Minimum 5 cm distance
between the electrodes; Separate arms of the trunk for 30 ° and 45 ° legs apart; The
environment duty will be neutral (no electric or magnetic field); It should be observed
body shape for the risk of any possible anomaly (edema, amputation, atrophy, scoliosis,
dystrophy); When prostheses or implants, is measured on the opposite side (KYLE et al,
2004); You can not use metal objects during the examination as earrings, bracelets,
watches and the like; There may be conducted in subjects who have pacemaker and who are
in pregnancy.
- Ultrasound diagnosis - will be used to analyze and measure the hypodermic layer of the
assessed region. This will be measured by a professional with training and experience
in this type of evaluation. The evaluator will collect the images in the basic period
(4 weeks before the start of treatment) before the first and after the last login
session. The results will be examined by a software in order to assess the thickness
and statistics of the images defined by the image of ultrasound. To collect the
individual will be in the supine position, the head is positioned above the navel and
the fat thickness is measured from the inner layer of the skin to the aponeurosis of
the rectus abdominis muscle in the middle of the Alba line area. The fat thickness
measurement is performed with linear probe (7.5 MHz) with a depth of 4 to 5 cm.
- Blood collection - The analyzes will be performed on serum obtained by venipuncture,
after an overnight fast of 12 hours. 02 will be held series of biochemical assessment
by patient, where each collection will last for a maximum of 30 seconds. The first
sample time is performed at baseline, i.e., before the control period. The second
collection will be held after the end of treatment Focused Ultrasound Cavitational.
After harvesting, the material is centrifuged at 3500 rpm / 10 minutes and then the
analysis will be performed. Samples will be collected by a person trained for this,
with latex glove use. They will be analyzed: total cholesterol, triglycerides, HDL
cholesterol, LDL cholesterol, glucose, urea and creatinine.
- Photo documentation - To carry out the photos, there will be a standard procedure in
order to maintain quality, the angle and the light always the same, so that the
observed results can be compared reliably. Initially, patients using swimsuits, will be
photographed standing in front and lateral planes (both sides) parallel to the plane of
the camera sensor. The camera is mounted on the tripod, level and horizontal position,
with the 105mm lens will be placed in proper height for framing the abdominal region,
and at a distance of 1 meter. The flash is mounted on the hot shoe of the camera, set
in TTL mode with the driven diffuser and will have its head directed forward. The
camera will be displayed in manual mode, with f5.6 aperture, shutter speed to 1/60
second and ISO 200. The images will be taken in the base period and after the treatment
and will be recorded in RAW format. The computational treatments on the images will be
made in batch, so that all images suffer the same treatment and will be transformed
into shades of gray. For image analysis, randomization of the resulting photographs
will be held, and they will be delivered to two blind evaluators (physiotherapists) who
will be invited to participate in the project to carry out this analysis. They will not
know which patient images belong, or what the correct order of application of images.
The evaluation will be as follows: both receive the photos in random order and will
have to put them in progression order of the sessions, in 2 times: before and after
treatment. After the correct organization, assess images qualitatively. Importantly,
the designated evaluator will be a person with extensive knowledge about the procedure.
The photographic analysis will be performed in two stages:
Step 1: The evaluators will receive slides with 6 photos for each patient, in random order
(will be photographs in black and white, not to interfere in the result). The evaluator will
classify the images in the order of 1 to 2, being 1 before treatment, after treatment and 2
referring to the reduction of localized fat deposits in the abdominal region (it is expected
that the treatment reduces the action of the abdominal region, so this sort order). They
will receive 3 slides for each patient, each containing images of the respective regions
measured: front, right profile and left profile.
Step 2: evaluators should classify the changes in the abdominal region, in one of the
degrees of the scale below: 0% = no change; 1% - 25% = little change; 25-50% = was no change
in terms of improvement, but nothing extremely significant; 50% or more = a change from the
reduction of localized fat in the abdominal area is visible / improved considerably.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04699669 -
A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02512822 -
Usefulness of Non-invasive Radiofrequency Therapy for Facial Contouring
|
N/A | |
Active, not recruiting |
NCT06005441 -
A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.
|
Phase 2 | |
Active, not recruiting |
NCT05736107 -
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
|
Phase 2 | |
Not yet recruiting |
NCT03160976 -
Cryolipolysis on Localized Adiposity
|
N/A | |
Completed |
NCT03871556 -
Diagnostic Ultrasound for Measuring Fat of the Body
|
N/A | |
Completed |
NCT02098811 -
Evaluation of the Safety and Precursors of Efficacy
|
N/A | |
Active, not recruiting |
NCT04553627 -
Feasibility of Producing the Appearance of a Gluteal Lift Post Cryolipolysis
|
N/A | |
Completed |
NCT01842802 -
Clinical Investigation of Non Invasive Fat Reduction
|
N/A | |
Completed |
NCT04698642 -
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat
|
Phase 2 | |
Completed |
NCT02052622 -
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
|
Phase 3 | |
Completed |
NCT04897412 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
|
Phase 2 | |
Completed |
NCT03682471 -
Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)
|
||
Completed |
NCT05234736 -
A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
|
Phase 2 | |
Completed |
NCT04575467 -
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
|
Phase 2 |